Myeloma Cancer Trials
54767414SMM3001
54767414SMM3001 – A phase III randomized, multicenter study of subcutaneous daratumumab versus active monitoring in subjects with high-risk smoldering multiple myeloma.
-
What type of cancer? What stage?
- Smoldering multiple myeloma.
-
Who is eligible?
- Diagnosed within 5 years.
-
How will I be treated?
- Daratumumab – an antibody-based drug, directed against CD38.
For physicians: more information about this specific trial at clinicaltrials.gov.
-
Metairie, LA 70006
504.503.6289 More information -
Metairie, LA 70006
504.456.5000 More information -
Metairie, LA 70006
504.883.2968 More information
/
View All